501 Boylston Street
About Karuna PharmaceuticalsKaruna Pharmaceuticals is a clinical-stage company targeting muscarinic receptors for the treatment of CNS disorders.
CEO: Andrew Miller
37 articles with Karuna Pharmaceuticals
Karuna Therapeutics Reports First Quarter 2022 Financial Results and Provides General Business Update
Karuna Therapeutics, Inc. announced financial results for the first quarter of 2022 and provided a general business update.
Karuna Therapeutics, Inc. announced that Andrew Miller, Ph.D., founder and chief operating officer, will participate in a fireside chat at the 2022 RBC Capital Markets Global Healthcare Conference on Tuesday, May 17, 2022, at 8:00 a.m. ET.
Zai Lab, a China-focused biopharma company that focuses on treatments for cancer and autoimmune diseases, announced positive data for its clinical trial on Zejula (niraparib) for ovarian cancer.
First Moscow State Medical University has paused recruiting new patients for its ongoing clinical trials following a disruption in the university’s ability to receive clinical trial samples.
On Sunday, Boehringer Ingelheim tweeted a message of support for Ukraine, and announced it was standing in solidarity with the embattled Eastern-European country.
Karuna Therapeutics Reports First Quarter 2021 Financial Results and Provides General Business Update
$571.3 million in cash expected to fund operations, including multiple milestones, for at least 12 months following the potential New Drug Application (NDA) submission of KarXT in schizophrenia
Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, announced that senior management is scheduled to participate in the following upcoming virtual investor conferences:
Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, announced that senior management will participate in the following upcoming virtual investor conferences:
Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, announced that it has commenced an underwritten public offering of $200.0 million of its common stock.
Karuna Therapeutics Reports Third Quarter 2020 Financial Results and Provides General Business Update
$344.9 million in cash, cash equivalents and investment securities expected to fund multiple milestones, including progressing KarXT to NDA submission, and operations for at least the next three years
Multi-year drug discovery collaboration leveraging behavioral and physiological phenotypic screening and machine learning to identify novel neuropsychiatric drug candidates
March 26, 2020 11:00 UTC Karuna Therapeutics to Participate in Stifel’s 2 nd Annual CNS Day Virtual Event BOSTON--( BUSINESS WIRE )-- Karuna Therapeutics, Inc. (Nasdaq: KRTX), a clinical-stage biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with disabling and potentially fatal neuropsychiatric disorders and pain, today announced that Steve Paul, M.D., chief executive officer, president and chairman of Karuna The
Karuna Therapeutics Reports Third Quarter 2019 Financial Results and Provides General Business Update
Phase 2 clinical trial of KarXT for the treatment of acute psychosis in patients with schizophrenia remains on track with topline data expected in late 2019
Karuna Therapeutics Reports Second Quarter 2019 Financial Results and Provides General Business Update
Karuna Therapeutics, Inc. announced financial results for the second quarter 2019 and provided a general business update.
The company is working on developing therapies for neuropsychiatric diseases. Karuna is expecting data from a Phase II clinical trial later this year of KarXT xanomeline/trospium chloride, a muscarinic receptor modulator, to treat acute psychosis associated with schizophrenia.
6/27/2019Two of this week’s biotech startup initial public offerings, BridgeBio and Adaptive Biotechnologies, have market values exceeding the magic $1 billion mark, and have recently launched initial public offerings (IPOs), but also increased their fundraising goals.
A summary of IPOs from companies in the biotech and pharma world since April 1, 2019.
4/29/2019Four biotech companies recently filed with the U.S. Securities and Exchange Commission their plans for initial public offerings (IPO). Let’s take a look.
Karuna Therapeutics Files Confidential Submission of Draft Registration Statement for Proposed Initial Public Offering
Karuna Therapeutics, Inc. announced that it has previously confidentially submitted a draft registration statement on Form S-1 with the Securities and Exchange Commission relating to the proposed initial public offering of its common stock.
Funding to drive investigation of further potential indications for lead product candidate, KarXT First U.S. Patent awarded for KarXT